Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein k, m, n, p, q, X, Y, Z, Ar, R1, R2, R3 and R4 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Abstract: Data may be marshalled from a managed runtime environment to an unmanaged environment by using a compiler to calculate argument offsets and generate marshalling language code.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein m, n, p, Ar, X, R1, R2, R3, R4, R5 and R6 are as defined herein. Also provided are compositions comprising, methods of preparing, and methods of using the subject compounds.

Abstract: Methods and apparatus to provide a modular native method invocation (NMI) system are described herein. In an example method, NMI information associated with an NMI call from one or more virtual machines is received. The NMI information is translated via an NMI adapter. To generate a native stub, the translated NMI information is provided to a modular NMI component.

Abstract: The invention provides compounds of the formula I: and pharmaceutically acceptable salts or prodrugs thereof, wherein m, n, p, q, X, Y, Z, A, R1, R2, R4, R5, R6, R7, R8, R9 and R10 are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

Abstract: The present invention provides a compound of the formula: a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R8, R9, Y, Z1, m, n, and p are as defined herein. The present invention also provides compositions comprising, methods for using, and methods for preparing Compound of Formula I.

Abstract: Compounds of the formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, X, Y and m are as defined herein. Also provided are compositions comprising, methods for using, and methods for preparing compound of formula (I).

Abstract: Compounds of the formula: or pharmaceutically acceptable salts or prodrugs thereof, where each of n and p independently is 2 or 3, Y is —SO2— or —SO2—N(R10)—, Z1 is CH or N, and R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined herein. The compounds have selective 5-HT6 affinity and are useful in the treatment of certain CNS disorders. Also provided are compositions comprising, methods for using, and methods for preparing Compounds of Formula I.

Abstract: This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula (I): wherein Ar, R1, R2, R3 or R4 are as defined in the specification, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Abstract: The present invention provides a compound of the formula: a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, and n are as defined herein. The present invention also provides compositions comprising, methods for using, and methods for preparing Compound of Formula I.

Abstract: The invention provides compound of the Formula: 1

Abstract: The invention provides compound of the Formula: 1

Abstract: The present invention provides a compound of the formula: 1

Abstract: The present invention provides a compound of the formula: 1

Abstract: This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula (I): 1

Abstract: The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT.sub.2B -antagonists. The 5-HT.sub.2B antagonist is a compound of the formula: ##STR1## wherein: R.sup.1 is hydrogen, alkyl, lower alkoxy, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, --NR.sup.6 R.sup.7, --CO.sub.2 R.sup.8, --O(CH.sub.2).sub.n R.sup.9, or lower alkyl optionally substituted with hydroxy, alkoxy, halo, or aryl; in whichn is 1, 2, or 3;R.sup.6 and R.sup.7 are hydrogen or lower alkyl;R.sup.8 is hydrogen or lower alkyl; andR.sup.9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;R.sup.2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;R.sup.3 is optionally substituted aryl other than pyridyl, thienyl, or furanyl;R.sup.4 is hydrogen, lower alkyl, cycloalkyl, alkenyl, acyl, amino, amido, aryl, --(CH.sub.2).sub.m NR.sup.10 R.sup.

Abstract: The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT.sub.2B -antagonists.

Abstract: The disclosed pyrimidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, in particular use as selective 5HT.sub.2B -antagonists. The invention is also directed to formulations and methods for treatment.

Abstract: Asymmetric synthesis using a novel catalyst comprising the formula: ##STR1## and which has utility in areas such as epoxidation of olefins.

Abstract: A novel catalyst comprising the formula: ##STR1## and which has utility in areas such as epoxidation of olefins.